Executive Viability Abstract
This feasibility study evaluates the establishment of a state-of-the-art precision medical robotics manufacturing facility in Switzerland. Given the country's strategic position in the MedTech hub of Europe, existing talent pool, and favorable regulatory environment for high-end precision engineering, the project presents a robust case for investment. The facility will focus on surgical assistants, micro-robotic instruments, and AI-integrated diagnostic hardware.
Return on Investment
24.5% over 5 years
Payback Span
4.2 years
Net Present Value
$52.4 Million
IRR Index
19.8%
## Market Analysis
The global medical robotics market is projected to reach $25 billion by 2030, with a CAGR of 16.5%. Switzerland offers a unique 'MedTech Valley' ecosystem. Key growth drivers include the aging population and the push for minimally invasive surgeries (MIS). Competitor analysis shows a gap in specialized micro-robotics which this facility aims to fill.
## Capex Summary
Total estimated Capex is $35,000,000. This includes $12M for specialized CNC and cleanroom equipment, $8M for facility acquisition/leasing in the Zurich or Lausanne tech corridors, $10M for R&D and initial prototype testing, and $5M for operational licensing and workforce onboarding.
## Revenue Model
The model is based on a dual-stream approach: 1. Direct Sales of robotic units (averaging $1.2M per unit) and 2. Recurring Service/Maintenance contracts (15% of unit cost annually). Secondary revenue includes software licensing for AI-driven navigation modules.
## Risk Assessment
Key risks include stringent Swissmedic and EU MDR certification timelines, high cost of labor in Switzerland, and supply chain dependencies for rare-earth magnets and high-grade sensors.